Predictive risk of Ang2 plasma levels and main established CLL prognostic factors in relation to TTFT and overall survival (univariate Cox models)
Factor . | TTFT . | Overall survival . | ||||
---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Ang2 level ≥ 2459 pg/mL | 2.437 | 1.621-3.664 | < .001 | 3.566 | 1.496-8.499 | .004 |
Binet stages B-C | 8.883 | 5.527-14.277 | < .001 | 6.860 | 2.743-17.155 | < .001 |
IGHV mutation < 2% | 4.342 | 2.792-6.754 | < .001 | 3.749 | 1.453-9.675 | .006 |
CD38 expression ≥ 30% | 2.647 | 1.738-4.029 | < .001 | 3.178 | 1.330-7.592 | .009 |
ZAP-70 expression ≥ 20% | 2.422 | 1.577-3.720 | < .001 | 2.666 | 0.950-7.486 | .062 |
CD49d expression ≥ 30% | 2.903 | 1.715-4.913 | < .001 | 7.019 | 2.179-22.607 | .001 |
Intermediate/high FISH risk* | 4.215 | 2.766-6.423 | < .001 | 2.531 | 0.995-6.435 | .050 |
β2-Microglobulin ≥ 2.2 mg/L | 2.347 | 1.515-3.636 | < .001 | 17.727 | 2.369-132.633 | .005 |
Diffuse BM pattern | 3.750 | 2.017-6.972 | < .001 | 4.907 | 1.552-15.516 | .007 |
Factor . | TTFT . | Overall survival . | ||||
---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Ang2 level ≥ 2459 pg/mL | 2.437 | 1.621-3.664 | < .001 | 3.566 | 1.496-8.499 | .004 |
Binet stages B-C | 8.883 | 5.527-14.277 | < .001 | 6.860 | 2.743-17.155 | < .001 |
IGHV mutation < 2% | 4.342 | 2.792-6.754 | < .001 | 3.749 | 1.453-9.675 | .006 |
CD38 expression ≥ 30% | 2.647 | 1.738-4.029 | < .001 | 3.178 | 1.330-7.592 | .009 |
ZAP-70 expression ≥ 20% | 2.422 | 1.577-3.720 | < .001 | 2.666 | 0.950-7.486 | .062 |
CD49d expression ≥ 30% | 2.903 | 1.715-4.913 | < .001 | 7.019 | 2.179-22.607 | .001 |
Intermediate/high FISH risk* | 4.215 | 2.766-6.423 | < .001 | 2.531 | 0.995-6.435 | .050 |
β2-Microglobulin ≥ 2.2 mg/L | 2.347 | 1.515-3.636 | < .001 | 17.727 | 2.369-132.633 | .005 |
Diffuse BM pattern | 3.750 | 2.017-6.972 | < .001 | 4.907 | 1.552-15.516 | .007 |
Intermediate/high-risk cytogenetic indicates 11q−, 17p−, or trisomy 12.